





Appendix Table of Contents

Appendix Figure S1: CRISPR/Cas9-mediated knockout of USP22 in HT-29 cells does not affect TB-induced apoptotic cell death.....	P1
Appendix Figure S2: HT-29 USP22 KO (2g) cells display a comparable number of cells re-expressing USP22 PAM, USP22 PAM C185S or USP22 PAM C185A.....	P2
Appendix Figure S3: CRISPR/Cas9-mediated knockout of USP22 in NB4 cells does not affect TB-induced apoptotic cell death.....	P3
Appendix Figure S4: CRISPR/Cas9-mediated knockout of USP22 does not alter TBZ-induced cell death in MEFs and the macrophage cell lines Raw264.7 or J774A.1.....	P4
Appendix figure S5: HeLa cells ectopically expressing RIPK3 K-to-R mutants display a homogeneous number of RIPK3-expressing cells after Dox treatment	P5
Appendix Figure S6: siRNA mediated knockdown of USP22 in RIPK3 K518R- or RIPK3 3xKR-reconstituted HeLa cells does not affect sensitivity to TBZ-induced necroptotic cell death	P6
Appendix figure legends.....	P7








Appendix Figure S4

A




B



C




D




E



F





Appendix Figure S1: CRISPR/Cas9-mediated knockout of USP22 in HT-29 cells does not affect TB-induced apoptotic cell death

HT-29 CRISPR/Cas9 control (Ctr) and USP22 KO cells were treated for 72 h, as indicated, with 0.5 μ M BV6 and 1 ng/ml TNF α . Cell death was determined by analysis of PI-positive nuclei.

Data information: Data represent mean \pm SD; NS: not significant, by unpaired 2-tailed Student's t-test. Three independent experiments are shown.

Appendix Figure S2: HT-29 USP22 KO (2g) cells display a comparable number of cells re-expressing USP22 PAM, USP22 PAM C185S or USP22 PAM C185A

- A** USP22 expression was quantified using anti-USP22 immunofluorescence staining in HT-29 CRISPR/Cas9 control (Ctr) cells and in USP22 KO cells re-expressing empty vector (EV), FLAG-HA-USP22 PAM (USP22 PAM) or the corresponding mutants C185S and C185A. Scale bar represents 100 μ m.
- B** Quantification of the percentage of TRITC-positive HT-29 cells after anti-USP22 immunofluorescence staining.

Data information: Data represent mean \pm SD; ***P < 0.001; **P < 0.01, by unpaired 2-tailed Student's t-test. Three independent experiments are shown.

Appendix Figure S3: CRISPR/Cas9-mediated knockout of USP22 in NB4 cells does not affect TB-induced apoptotic cell death

- A** NB4 CRISPR/Cas9 control (Ctr) and USP22 KO cells were analyzed for USP22 expression by Western blotting. β -Actin served as loading control.
- B** NB4 control and USP22 KO cells were stimulated with 20 μ M zVAD.fmk, 1 μ M BV6 and 10 ng/ml TNF α . Cell death was measured after 48 h by analysis of PI-positive nuclei.

Data information: Data represent mean \pm SD; NS: not significant, by unpaired 2-tailed Student's t-test. Three independent experiments are shown.

Appendix Figure S4: CRISPR/Cas9-mediated knockout of USP22 does not alter TBZ-induced cell death in MEFs and the macrophage cell lines Raw264.7 or J774A.1

- A** MEF CRISPR/Cas9 control (Ctr) and USP22 KO cells were analyzed by Western blotting for USP22 expression. GAPDH served as loading control.
- B** MEF control and USP22 KO cells were pre-treated with 10 μ M Nec-1s and 20 μ M Dabrafenib for 1 h. Cells were stimulated with 20 μ M zVAD, 5 μ M BV6 and 10 ng/ml TNF α for 24h. Cell death was determined by analysis of PI-positive nuclei.
- C** Raw264.7 CRISPR/Cas9 control (Ctr) and USP22 KO cells were transfected with non-silencing control siRNA (sictr) or siRNAs against USP22 (siUSP22) for 48 h at 20 nM. USP22 expression was monitored by Western blotting. GAPDH served as loading control.
- D** Raw264.7 control and USP22 KO cells were transfected with non-silencing control siRNA (sictr) or pooled siRNAs against USP22 (siUSP22) for 48 h at 20 nM. Cells were pre-treated with 10 μ M Nec-1s and 20 μ M GSK'872 for 1 h before being stimulated with 20 μ M zVAD, 5 μ M BV6 and 10 ng/ml TNF α for 24h. The percentage of PI-positive cells was assessed by fluorescence-based PI staining.
- E** J774A.1 CRISPR/Cas9 control (Ctr) and USP22 KO cells were transfected with non-silencing control siRNA (sictr) or siRNAs against USP22 (siUSP22) for 48 h at 20 nM. USP22 expression was monitored by Western blotting. GAPDH served as loading control.
- F** J774A.1 control and USP22 KO cells were transfected with non-silencing control siRNA (sictr) or pooled siRNAs against USP22 (siUSP22) for 48 h at 20 nM. Cells were pre-treated with 10 μ M Nec-1s and 20 μ M GSK'872 for 1 h prior to stimulation

with 20 μM zVAD, 5 μM BV6 and 10 ng/ml $\text{TNF}\alpha$ for 24h. The percentage of PI-positive cells was assessed by fluorescence-based PI staining.

Data information: Data represent mean \pm SD; NS: not significant, by unpaired 2-tailed Student's t-test. Three independent experiments are shown.

Appendix figure S5: HeLa cells ectopically expressing RIPK3 K-to-R mutants display a homogeneous number of RIPK3-expressing cells after Dox treatment

- A** HeLa cells expressing Dox-inducible RIPK3 WT, D160N, K42R, K351R, K518R, 2xKR and 3xKR were treated with 1 $\mu\text{g/ml}$ Dox overnight. RIPK3 expression was imaged using FITC-labeled anti-RIPK3 immunofluorescence staining. Scale bars represent 250 μm .
- B** Quantification of the percentage of FITC-positive cells treated with 1 $\mu\text{g/ml}$ Dox overnight after anti-RIPK3 immunofluorescence staining.

Data information: Data represent mean \pm SD; NS: not significant, by unpaired 2-tailed Student's t-test. Three independent experiments are shown.

Appendix Figure S6: siRNA mediated knockdown of USP22 in RIPK3 K518R- or RIPK3 3xKR-reconstituted HeLa cells does not affect sensitivity to TBZ-induced necroptotic cell death

- A** HeLa cells expressing Dox-inducible RIPK3 WT, K518R, 2xKR or 3xKR were transfected with non-silencing control siRNA (sictr) or siRNAs against USP22 (siUSP22) for 48 h at 20 nM and treated with 1 μ g/ml Dox. RIPK3 and USP22 expression was analyzed by Western blotting. β -Actin served as a loading control.
- B** HeLa cells expressing Dox-inducible RIPK3 WT, K518R, 2xKR or 3xKR were transfected with non-silencing control siRNA (sictr) or pooled siRNAs against USP22 (siUSP22) for 48 h at 20 nM and treated with 1 μ g/ml Dox, as indicated. Cells were pre-treated with 20 μ M zVAD.fmk and 5 μ M BV6 for 1 h after 10 ng/ml TNF α was added for 4 h. The percentage of PI-positive cells was assessed by fluorescence-based PI staining.

Data information: Data represent mean \pm SD; **P < 0.01; ***P < 0.001; NS: not significant, by unpaired 2-tailed Student's t-test. Three independent experiments are shown.